返回
J
Juan Carlos Hernández‐Boluda
hospital clinico de valencia-incliva
44H指数
355论文数
7.1K被引数
收录论文 117
发表时间
Spleen volume reduction and transfusion independence with momelotinib vs ruxolitinib and associated overall survival with momelotinib in JAK inhibitor–naive patients with myelofibrosis and anemia: subgroup analyses of SIMPLIFY-1脾脏体积缩小和输血独立性:比较momelotinib与ruxolitinib,以及momelotinib相关的总生存期,在JAK抑制剂初治伴有贫血的骨髓纤维化患者中的亚组分析:SIMPLIFY-1研究。
Defining remission and relapse after allogeneic hematopoietic cell transplantation in myelodysplastic/myeloproliferative neoplasms and optimization of transplantation outcomes: Recommendations from the EBMT practice harmonisation and guidelines committee定义异基因造血细胞移植后骨髓增生异常/骨髓增生性肿瘤的缓解和复发,并优化移植结果:EBMT实践协调与指南委员会的建议
A European survey on allogeneic haematopoietic cell transplantation for myelofibrosis on behalf of the Chronic Malignancies Working Party of the EBMT: focus on ‘real world’ experience of JAK inhibitors, splenomegaly management and novel agents in the transplant algorithm一项由EBMT慢性恶性疾病工作组代表进行的关于异基因造血细胞移植治疗骨髓纤维化的欧洲调查:聚焦于JAK抑制剂的“真实世界”经验、脾肿大管理以及移植算法中的新型药物
Corrigendum to: “Comparison of three strategies of GvHD prophylaxis after T-cell replete haploidentical hematopoietic transplantation: Tacrolimus vs calcineurin inhibitors-MMF vs sirolimus-MMF” Journal: Transplant Cell Ther. 2024 Oct;30(10):1025.e1-1025.e14. doi: 10.1016/j.jtct.2024.07.027勘误:Comparison of three strategies of GvHD prophylaxis after T-cell replete haploidentical hematopoietic transplantation: Tacrolimus vs calcineurin inhibitors-MMF vs sirolimus-MMF
期刊:Transplant Cell Ther. 2024 Oct;30(10):1025.e1-1025.e14. doi: 10.1016/j.jtct.2024.07.027

